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A B S T R A C T
Eugenol is a phenolic compound largely found in the clove essential oil that possesses promising biological activity.
However, its low water solubility is a major concern and encapsulation is an alternative to improve water affinity.
The objective of this work was to produce nanostructured lipid carriers (NLC) by hot homogenization/ultrasound
emulsification and to evaluate the effect of free and encapsulated clove oil on the in vitro cholinesterase enzymes
modulation using Drosophila melanogaster (DM) tissue. The NLC composed of a natural wax (carnauba or beeswax)
and crodamol showed an average diameter between 121 and 367 nm with good dispersion and colloidal stability.
The spherical shape and solid character together with the semi-crystalline environment confirm the formation of
NLC. DSC analysis indicated polymorphic transition events of the waxes. In vitro tests using DM demonstrated that
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free clove oil showed a good inhibition of the butyryl and acetylcholinesterase enzymes above a concentration of
10mM, with IC50 values of 4.3 and 3.5mM, respectively. The dispersions of the NLC loaded with clove oil showed
a decrease in the IC50 enzymes values, indicating the preservation of the clove essential oil and suggesting an
increased in the solubility. Results indicate that NLC dispersions have good potential to be used for foods and
cosmetic aqueous formulations possessing biological activity.
1. Introduction
Phenolic compounds are found naturally in many fruits, vegetables,
and nuts, as secondary metabolites. Chemically, these compounds have
one or more hydroxyl group attached to a benzene ring and play an
important role in the human diet by exerting various biological effects
such as free radical scavenging, metal chelation, modulation of enzy-
matic activity and altering signal transduction pathways [1–3]. Eugenol
is the major component of clove oil, approximately 90–95%, re-
sponsible for the specific clove aroma and known as a good agent for
human health due to the biological activities and also for the specific
clove oil aroma [3–12].
The antioxidant potential of eugenol was extensively studied in the
literature [6,10,13–17], and some studies associating this antioxidant
property with acetylcholinesterase inhibition were also reported [3,7].
The acetylcholinesterase (AChE - EC 3.1.1.7) is an enzyme responsible
for the termination of cholinergic signaling by hydrolyzing acetylcho-
line (ACh) and the inhibition of AChE is effective in the treatment and
management of Alzheimer’s disease, multiple system atrophy, and other
conditions [3,7,18]. Acetylcholine hydrolysis can also be catalyzed by
butyrylcholinesterase (BChE - EC 3.1.1.8, also known as serum choli-
nesterase or pseudo-cholinesterase), a related and less-specific enzyme
[18], however, to the best of the authors knowledge there is no report
in literature about eugenol as a potential modulator of BChE activity.
Although some research groups have been investigating eugenol as
potential AChE inhibitor [19–22] all studies involve the use of the clove
oil in the free form, and the concentration needed to ensure an effective
activity as AChE inhibitor may be difficult to reach in actual biological
systems due to the hydrophobic character of the essential oil. In addi-
tion, eugenol is volatile and chemically unstable in the presence of air
and light, and its encapsulation may be a positive alternative since the
main objective is to protect the bioactive compound against the adverse
environmental conditions. In this way, the incorporation of the essen-
tial oil in a lipid matrix may improve the solubility and the bioavail-
ability in the medium. The lipid nanoparticles are generally made by
biodegradable lipids that can be solid at room and body temperature
and possess several advantages like high drug loading, increased drug
stability, controlled drug release, and enhanced penetration of drugs
into the skin or any other target [23–25]. The nanostructured lipid
carriers (NLC) loaded with essential oils can be easily incorporated in
water-rich cosmetic and food formulations, expanding its range of ap-
plication and improving bioactive compound shelf life as already re-
ported by other works [26–28].
In the present work clove oil, a great source of eugenol, was in-
corporated in NLC made from either carnauba wax (CW) or beeswax
(BW) using the hot homogenization/ultrasound emulsification tech-
nique. The waxes obtained from natural sources like carnauba and bees
are composed of hydrocarbons, alcohols, free acids, esters, and other
materials, which have many advantages due to the low toxicity and
biocompatibility making the final product interesting for several ap-
plications [29]. The obtained aqueous NLC dispersions were evaluated
in relation to particle diameter, distribution, and morphology, clove oil
encapsulation efficiency, as well as by chemical and thermal analyses.
In addition, AChE and BChE activities were verified in vitro for the free
and encapsulated clove oil using a Drosophila melanogaster (DM) tissue
as biological model. DM is widely used in biological tests due to the
great similarity with the human genetic sequence, allowing the un-
derstanding of complex biological problems [30,31] and it was used in
the present study as an alternative biological model to test the NLC
loaded clove oil effects in the cholinergic enzymes AChE and BChE.
2. Experimental
2.1. Materials
NLC production involved the use of carnauba wax (CW) and
beeswax (BW) as solid lipids kindly donated by GM Ceras Ltda/ Brazil,
crodamol GTCC (saturated triglyceride from coconut oil, Alpha
Química, Brazil) as liquid lipid, clove oil (CO - 92% Eugenol) from
Ferquima/Brazil as bioactive compound, polysorbate 80 (Tween 80 –
Sigma-Aldrich) as surfactant, and distilled water as aqueous phase. It is
worth noting that Tween 80 and crodamol are considered safe food
ingredients by FDA and were used in NLC formulations [32]. For AChE
and BChE activities tests were used acetylthiocholine iodine (ASCh),
butyrylthiocholine iodide (BSCh),5,5′-Dithiobis(2-nitrobenzoic acid)
(DTNB, 98% purchased from Sigma-Aldrich/Brazil) and methanol
(P.A., NEON). Mono and dibasic potassium phosphate (NEON) were
used to prepare TFK buffer and tris-(hydroxymethyl)aminomethane
Table 1
Composition of the organic phase of carnauba wax (CW) and beeswax (BW) NLC, average particle diameter (Dp), polydispersity index (PdI), and encapsulation
efficiency (EE) of the nanoparticles at day 1, 15 and 30.
Sample Wax (g) Crod (g) CO (g) Dp (nm)/ PdI EE (%)
Day 1 Day 15 Day 30 Day 1 Day 15 Day 30
CW1 3 – – 1489/0.27 – – – – –
CW2 2 – – 613/ 0.31 – – – – –
CW3 1 – – 178/ 0.27 301/ 0.43 381/ 0.52 – – –
CW4 0.9 0.1 – 121/ 0.08 122/ 0.09 125/ 0.12 – – –
CW5 0.9 0.075 0.025 126/ 0.11 128/ 0.11 130/ 0.10 58 ± 0 58 ± 0 56 ± 1
CW6 0.9 0.05 0.05 150/ 0.19 146/ 0.18 152/ 0.16 60 ± 2 61 ± 3 58 ± 1
BW1 3 – – 443/0.165 – – – – –
BW2 2 – – 320/ 0.12 – – – – –
BW3 1 – – 324/ 0.15 617/0.58 698/0.64 – –
BW4 1.8 0.2 – 227/ 0.09 229/ 0.09 231/ 0.12 – – –
BW5 1.8 0.1 0.1 272/ 0.09 242/ 0.09 260/ 0.13 66 ± 1 66 ± 0 64 ± 0
BW6 1.8 0.05 0.15 342/ 0.08 349/ 0.06 357/ 0.10 64 ± 1 65 ± 0 63 ± 2
BW7 1.8 0.02 0.18 368/ 0.10 394/ 0.12 401/ 0.14 63 ± 0 63 ± 0 60 ± 2
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(Tris) from Sigma-Aldrich. All other chemicals were analytical grade
and purchased from local sources. Drosophila melanogaster (DM) wild
type flies were obtained from the National Species Stock Center
(Bowling Green, OH, USA) and were used as source of biological tissue.
2.2. Preparation of the wax nanoparticles by ultrasound emulsification
The NLC production was conducted by the hot homogenization/ultra-
sound emulsification technique described elsewhere with some modifica-
tions [33]. Initially, the lipid and aqueous phases were prepared separately.
The aqueous phase was prepared dissolving 3%wt of Tween 80 in water
(10mL). The lipid phase was composed of different amounts of CW or BW,
crodamol and clove oil as shown in Table 1. In sequence, the physical
mixture of the organic components was made under heat (10 °C above the
melting point of the wax) and after complete melting, the aqueous phase
(previously heated to the same temperature) was added to the organic
phase. Both phases were intensely homogenized for 15min in a hot bath
with orbital agitation to form a coarse emulsion. Then, the emulsion was
submitted to high-energy emulsification by an Ultrasonic Dismembrator
(Fischer Scientific 500, 400W) at 50% of amplitude in pulsed regime for
1min (30 s on 10 s off) in order to reduce the melted droplets to the na-
nometric range. Finally, the melted wax nanodroplets were cooled in cold
water (90mL at 4 °C) to form solid nanoparticles (final volume 100mL).
2.3. Particles characterization
Intensity average particle size (Dp) and polydispersity index (PdI) of
the NLC were determined by Dynamic Light Scattering (DLS) using a Zeta
Sizer Nano S (Malvern Instruments). The formulations were analyzed
right after the production (Day 1) and after 15 and 30 days of storage at
room temperature (Day 15 and 30). For that, the samples were properly
diluted in water and measured at 25 °C in a glass cuvette. Transmission
Electron Microscopy (TEM 100 kV JEM-101) was carried out to in-
vestigate the particle morphology of the CW and BW NLC. For that, each
sample was diluted in distilled water up to 0.1%wt solids, and then, one
drop of each diluted sample was placed on a carbon-coated 400 mesh
copper grid of and dried overnight under room conditions. The chemical
analysis was performed by Fourier Transform Infrared (FTIR) spectro-
scopy using a Shimadzu IRPrestige-21. The pure clove oil, bulk waxes,
and lyophilized NLC samples were analyzed using the potassium bromide
(KBr) pellet method. Spectra were taken in the range of 4000 to 400
cm−1 with 32 cumulative scans. Lyophilized NLC samples and bulk
waxes were analyzed by Differential Scanning Calorimetry (DSC 4000
Perkin Elmer) under inert atmosphere (N2, 20mL.min−1), from 0 to
100 °C at a heating rate of 10 °C.min−1. The thermal history was re-
moved under a heating rate of 20 °C.min−1 and cooling rate of
−20 °C.min−1. DSC heating and cooling curves were obtained from the
second and first run, respectively. Calorimetric parameters including the
melting temperatures (Tm), melting and cooling enthalpies enthalpy
(ΔH), width at half height (ΔT1/2) and onset temperatures (Tonset) were
analyzed using the Pyris Manager software (PerkinElmer). The crystal-
linity index (CI) of NLC formulations were calculated using Eq. (1):
= ×CI H
H
100%mNLC
mwax (1)
where, ΔHmNLC and ΔHmwax are the melting enthalpy of the NLC sample
and pure wax, respectively [29,34].
The clove oil encapsulation efficiency (EE) in the NLC matrix was
determined by the analysis of the free clove oil in the aqueous phase of
the NLC dispersion. The NLC dispersions containing clove oil (500 μL)
were ultra-filtrated using an Eppendorf with an Amicon Ultra 0.5
coupled to a filter (Millipore®, 100 kDa) at 10,000 rpm for 10min. An
aliquot of the filtered liquid was adequately diluted in ethanol, trans-
ferred to a quartz cuvette and analyzed in the wavelength of 280 nm in
a UV–vis spectrophotometer (Hitachi U-1900). The concentration of
free clove oil was calculated as previously described elsewhere [35].
2.4. Tissue preparation
The Drosophila Melanogaster homogenate was prepared as described
elsewhere with minor modifications [31]. Adults flies (both gender)
were maintained and cultured in cornmeal medium (2% w/v sucrose,
1.6% w/v powdered milk, 0.2% salt, and 0.05% w/v methylparaben)
during 12 h dark/light cycle conditions at constant temperature
(22–24 °C) and humidity (45–65 %). One hundred adult flies were cold
anesthetized in a domestic freezer and manually homogenized in 1mL
of Tris−HCl solution (50mM, pH 7). In sequence, samples were cen-
trifuged at 12,000 rpm for 10min and the supernatant (S1) was used as
DM homogenate in the in vitro AChE and BChE tests.
2.5. In vitro cholinergic activity
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) ac-
tivity were measured by the assay described by Ellman et al. [36]
considering some modifications described by Hammond and Forster
[37] and Dohi et al. [7] using DM homogenate as enzymes source. The
IC50 was determined plotting the graphs and line equations between the
clove oil concentration versus the I% to each system.
Free clove oil: Initially, solutions with appropriate clove oil con-
centrations were prepared by sequential dilution of the essential oil in
methanol. In sequence, TFK (25 μL, 100mM) and S1 (12.5 μL) were
placed in a 96-well microplate and dissolved with 12.5 μL of each
previously prepared clove oil methanolic solution. At this point, the
time zero (abs t0) reading was performed in a microplate reader
(Thermo-Plate Reader) at 405 nm. After a pre-incubation at 37 ± 1 °C
for 15min, DTNB (62.5 μL, 2mM) and substrate (12.5 μL, ASCh or BSCh
8mM) were added into the wells and then incubated at room tem-
perature for 15min. The absorbance of the final mixtures was measured
at the end of the incubation time (abs tfinal). A control mixture was
prepared by using 12.5 μL of pure methanol instead of the methanolic
oil sample. The inhibition percentage was determined by Eq. (2).
= ×I Abs
Abs
(%) 100 100sample
control (2)
where, Abssample is the absorbance of the sample containing clove oil
and Abscontrol is the absorbance of the control without the essential oil.
Clove oil-loaded NLC: Initially, appropriated NLC concentrations were
prepared by sequential dilutions of the NLC aqueous dispersion in water.
In sequence, 12.5 μL of TFK (100mM), 12.5 μL of methanol, and 12.5 μL
of DM homogenate were placed in a 96-well microplate and mixed with
12.5 μL of each previously prepared NLC dispersion. All the other pro-
cedures including incubation time and temperature, absorbance reading,
the addition of DTNB and substrates, and percentage of inhibition (I%)
were the same as those described for “Free clove oil as inhibitor”.
Otherwise, the control mixture was prepared using NLC dispersion with
no clove oil (blank sample) but with the same solids content.
2.6. Statistical analyses
Biological results are presented as mean ± standard deviation. One-
way ANOVA was used to investigate the significant difference in the in
vitro experiments following by Tukey post hoc test with 5% significance
level. Analyses were conducted on GraphPad Prism 5 software.
3. Results and discussion
3.1. Particles characterization
The NLC were produced using BW or CW and crodamol as matrix
material, and different formulations were tested with varying amounts
of wax as solid lipid, crodamol as liquid lipid, and clove oil as bioactive
compound. The formulations and Dp, PdI and EE results are presented
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in Table 1. Transmission Electron Microscopy images of selected sam-
ples are showed in Fig.1.
The use of carnauba wax as matrix material systematically resulted
in particles with higher Dp and PdI when compared to beeswax.
However, in all cases, Dp values between 120 and 1489 nm with narrow
distributions were found, which may be interesting depending on the
desired application. The carnauba wax formulations containing a single
lipid in organic phase (CW1, CW2, and CW3) showed a pronounced
increase of the Dp with increasing wax amount used, as compared to
the BW formulations, which may be associated to the CW higher chain
length, and consequently, higher viscosity [38]. The use of 10 wt%
(related to the organic phase, CW4 and BW4) of crodamol as liquid lipid
favored a noteworthy reduction in Dp as well as in the PdI for for-
mulations with either CW or BW. A similar effect was observed in other
studies [33,34] which related the reduction of the Dp to the decrease in
the organic phase viscosity, decreasing the resistance of the melted
droplets disruption during emulsification/sonication.
After the incorporation of the clove oil in the formulations, a slight
increase in Dp was visualized for all preparations, probably due to the
reduction of the crodamol percentage in the organic phase, but it was still
ensured a monomodal and homogeneous dispersion with PdI below 0.2.
The presence of the liquid lipid played an important role in the particle
stability of the formulations. The absence of crodamol in the formulation
resulted in a great increase in Dp and PdI after storage, while the for-
mulations containing 10wt% of crodamol (related to the organic phase)
showed just a slight increase in Dp and distributions for both waxes, still
showing a good colloidal stability. Results indicate that the SLN formula-
tions containing only wax were more susceptible to aggregation with an
increase on the Dp and PdI. On the other hand, the binary lipid NLC for-
mulations showed a slight change in Dp and PdI after storage, indicating
more stable structure, consequently, a lower disposition to aggregation.
TEM images confirmed the nanometric range of the lipid particles
with diameters compatible with those measured by DLS. The spherical
shape (almost oval for the BW NLC), smooth surface, and solid char-
acter indicate that no core-shell morphology was formed, but rather a
solid particle with the crodamol and the bioactive compound dis-
tributed uniformly in the lipid sphere. This solid/no core morphology is
usually expected for the NLC formulations composed of the mixture of
solid and liquid lipids. Although the use of a liquid lipid is essential for
drug accommodation it just ensures distances between the long fatty
acids chains from waxes forming imperfections in the crystal, allowing
room to active compound loading but not room enough to form a core
even at high liquid lipid amounts [32,39].
All formulations showed a good capacity to incorporate different
amounts of clove oil with EE around 60%, and beeswax formulations
(higher amount of dispersed phase) were able to incorporate higher
amounts of clove oil than the carnauba wax formulations. In addition,
even after 30 days of storage, no decrease was observed in the EE showing
that the bioactive compound had a good affinity for the NLC matrix.
Free clove oil, bulk CW and BW, and NLC formulations (without and
with the highest amount of clove oil) were analyzed by FTIR and the
spectra are shown in Fig.2.
Spectrum a shows typical eugenol peaks, including a large band
related to the hydroxyl group (OeH) stretch around 3550 and
3200 cm−1, peaks at 2950 and 2980 cm−1 related to axial deformation
of the groups CH2 and CH3. The peak at 1640 cm−1 is related to weak
axial deformation of the alkene group C]C, 1540 cm−1 to the axial
deformation of C]C of the benzene ring, at 1033 cm−1 a peak related
to aromatic CeH is observed and at 750 cm−1 out-of-plane angular
deformation related to CeH of the aromatic ring [40,41].
Spectra b and c show the peaks referent to carnauba wax and
beeswax. The regions 2925 and 2850 cm−1 are related to the symmetric
and asymmetric vibrations of the CH3 group and the peak at 714 cm−1
confirms the asymmetric angular deformation of the long hydrocarbon
chains CH2. Still, the peaks in the region of 1739 and 1103 cm -1 in-
dicate, respectively, the stretch of C]O from the o carboxyl groups and
CeO stretch from the ester group [42,43]. Although in lower intensity,
the same peaks were found in the NLC spectra (d, e, f, g), indicating
that the matrix material maintained the original characteristics after
the NLC production. On the other hand, no eugenol characteristic peak
Fig. 1. TEM micrographs of the NLC formulations (a) CW4, (b) CW6, (c) BW4 and (d) BW7. The scale bar of the figures a, b, c and d corresponding, respectively, to
0.2, 0.2, 0.5 and 2 μm.
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was found in spectra f and g (NLC formulations containing clove oil),
indicating the overlapping of the clove oil spectra with the waxes
spectra probably due to the low amount of the oil in the formulations as
already reported by other authors [44,45].
Fig. 3 shows second heating and first cooling runs of bulk waxes
(BW, CW), NLC formulations without (BW4/CW4) and with the highest
amount of clove oil (BW7/CW6) analyzed by DSC.
The heat flow curve for bulk BW showed an endothermic melting
peak with homogeneous melting and melting temperature (Tm) 57 °C
(Fig.3a). The NLC BW4 had a pre-melting (left shoulder) followed by
complete melting, which is associated to the presence of a high amount of
crodamol (10wt%) in the formulation creating a less crystalline en-
vironment and, consequently, melting at a lower temperature while a
more ordered structure melts at a higher temperature. The cooling curves
(Fig.3b) showed that the presence of crodamol in NLC BW4 assisted the
polymorphic transition of the lipid from β-modification to α-modification
[46], most dense packing and disordered aliphatic chain conformation,
respectively [46–49], confirming the presence of a less ordered structure.
On the other hand, formulation NLC BW7 (reduced amount of crodamol
(1wt%) and high amount of clove oil 9wt%) showed single melting and
cooling peaks similar to those found for the bulk wax, revealing the ab-
sence of polymorphic transitions. The less ordered crystal lattice is fa-
vorable for entrapping molecules and the increase in ΔH and decrease in
Tonset, Tm, CI, and ΔT1/2 (Table 2) for BW NLC formulations compared to
the bulk wax indicates that both nanoparticulate formulations possess a
portion of less ordered structures, but only BW4 with 10wt% of crodamol
presented α→β polymorphic transition.
Fig.3a also shows the heat flow curve for bulk CW with endothermic
and homogeneous melting peak and melting temperature (Tm) of 83 °C
while the CW NLC formulations showed a pre-melting at 58 °C followed
by the complete melting, consequently, reducing the Tonset and an in-
creasing ΔT1/2 of the NLC CW in relation to the bulk wax. The cooling
curves presented in Fig.3b show the polymorphism transition from β-
modification to α-modification in bulk CW and CW NLC. The result
suggests that bulk CW possesses a polymorphic nature and the presence
of a shoulder in melting peaks of the CW NLC may be related to the lipid
intermediates (β’-modifications) formed during the β→α-polymorphic
transition [38,44,49]. In addition, some authors associated these β’-
fractions to the interaction between the lipid and the emulsifier
Fig. 2. FT-IR spectra of (a) pure clove oil, (b) beeswax (BW), (c) carnauba wax (CW), (d) BW4, (e) BW7, (f) CW4, and (g) CW6.
Fig. 3. DSC heating (a) and cooling (b) enthalpies of carnauba wax (CW),
beeswax (BW), and formulations BW4, BW7, CW4 and CW6.
A.C. de Meneses, et al. Colloids and Surfaces A 583 (2019) 123879
5
[28,44]. Other study observed an increase in the left shoulder of the
DSC melting curves as the amount of carnauba wax was increased in the
formulation and related this thermal behavior directly with the SLN
production process and reduction of the particle size [44]. The differ-
ence in crystallization and melting temperatures, enthalpies, Tonset, and
the sharp decrease in CI between the nanoparticulate and bulk CW
samples indicates that the polymorphism of the crystals formed in the
NLC are less organized than in the pure wax. The decrease in crystal-
linity is favorable for compounds entrapment since lattice defects of the
lipid structure could offer room to accommodate the drugs, while
highly crystalline lipids would lead to drug expulsion [28].
The NLC formulations containing crodamol as liquid lipid showed a
semi-crystalline or less ordered structure than the bulk waxes. Similar
behavior was reported by other authors [45,50] that used binary lipid
combinations to entrap bioactive compounds, and the presence of a li-
quid lipid in the formulation decreased the crystallinity of the dispersed
phase, and consequently, improved the drug encapsulation efficiency. In
other words, the use of a liquid lipid increases the number of imperfec-
tions and leads to increased drug loading capacity and retention, which
composes the first model of NLC called imperfect type NLC [39]. These
results indicate that all BW and CW formulations containing a fraction of
crodamol could be used as a potential system for clove oil delivery. Based
on this, the samples containing the highest amount of clove oil were
selected for the in vitro AChE and BChE inhibition assays.
3.2. Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE)
inhibitory activity
Drosophila melanogaster homogenate was employed to determine the
in vitro inhibitory activity of AChE and BChE after the incubation with
different concentrations of free and encapsulated clove oil, the activity
inhibition (%) and IC50 (mM) are shown in Fig.4.
Drosophila melanogaster is the closest invertebrate model organism to
human based on the gene sequence similarity, and the high sensitivity to
toxic substances favors its use as a bioindicator to evaluate the biological
action of pharmacological agents [51,52]. The free clove oil dissolved in
methanol showed similar efficacy in the inhibition in both cholinergic
enzyme (AChE and BChE), and concentrations equal or above 10mM
were able to inhibit completely the enzymes. In this way, the IC50 of free
clove oil for AChE inhibition (3.5mM) was similar to the value found in a
previous work [7] that utilized electric eel as the enzyme source (Elec-
trophorus AChE type VI-S). Authors investigated the AChE inhibitory ef-
fect of many essential oil components, indicating that the eugenol pre-
sent in the clove oil plays the same role in the oil activity. Results suggest
that the free clove oil had similar activity against both AChE and BChE.
With the encapsulation of clove oil in CW and BW NLC it was
possible to decrease the IC50 values to less than 50% when compared to
the free clove oil at the same concentrations. This result indicates that
the incorporation of the essential oil in the lipid particles favored the
water affinity of the oil since no solvent (such as methanol) was used. A
similar result was found in other work that evaluated beta-carotene
nanodispersed in water and demonstrated a decrease in the
Table 2
DSC calorimetric parameters of waxes and NLC formulations: melting temperatures (Tm), recrystallization temperatures, heating and cooling enthalpies (ΔH), width
at half height (ΔT1/2) and onset temperatures (Tonset).
Melting
Parameter Carnauba wax Beeswax BW4 BW7 CW4 CW6
Tonset (ºC) 72.7 51.4 36.8 48.2 55.93 56.9
Tm (ºC) 83.3 57.6 56.4 52.9 77.9 79.2
ΔH (J/g) 186.0 149.3 142.1 135.5 134.1 133.3
CI (%) 100.0 100.0 95.1 90.7 72.1 71.7
ΔT1/2 (ºC) 8.9 13.6 12.8 9.9 10.7 9.4
Recrystallization
Parameter Carnauba wax Beeswax BW4 BW7 CW4 CW6
Tα (ºC) 68.7 – 38.3 – 59.0 60.1
Tβ (ºC) 74.4 51.0 44.2 45.2 69.2 69.4
ΔH (J/g) −197.0 −144.9 −149.5 −124.3 −135.9 −132.7
Fig. 4. AChE (a) and BChE (b) inhibitory activity (%) and IC50 (mM) of the free
clove essential oil, clove oil loaded into NLC of carnauba wax (CW6) and
beeswax (BW7). Values are mean ± SEM (n=4 per group). Significance de-
termined by one-way analyses of variance (ANOVA) followed by Tukey’s test.
*p < 0.05 in comparison with the control (100% of inhibition).
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nanoparticle average diameter increased the beta-carotene dis-
persibility in water and favored the AChE inhibition [31].
4. Conclusion
Clove essential oil was successfully incorporated in natural nanos-
tructured lipid carriers using beeswax or carnauba wax as matrix mate-
rials. The presence of a liquid lipid (medium chain triglycerides, cro-
damol) in the formulation led to the decrease in the average particles size
but the sizes distribution remained monodisperse. The solid lipid nano-
particles containing crodamol in formulation presented satisfactory
aqueous colloidal stability after 30 days of storage. The particles char-
acterization showed typical nanostructured lipid carrier properties as
solid morphology, semi-crystalline environment, and polymorphic tran-
sition events. The free clove oil and the solid lipid dispersion containing
encapsulated clove oil showed efficient in vitro acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE) inhibition in Drosophila mela-
nogaster tissue. In addition, nanostructured lipid formulations showed
high inhibition with an IC50 lower than the free clove oil. The free oil was
tested in the presence of a good solvent (methanol) while the nano-
particles were evaluated in water only, meaning that the oil bioactivity
was potentialized in aqueous medium which is important in a commer-
cial point of view in food and cosmetic applications.
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